J Katz1, S K Khatry, M D Thapa, O D Schein, E Kimbrough Pradhan, S C LeClerq, K P West. 1. Johns Hopkins Bloomberg School of Public Health, Division of Disease Prevention and Control, Department of International Health, Room W5009, 615 N Wolfe Street, Baltimore, MD 21205-2103, USA. jkatz@jhsph.edu
Abstract
AIM: To assess whether povidone-iodine provided any benefit over and above a standard regimen of antibiotic therapy for the treatment of corneal ulcers. METHODS:All patients diagnosed with corneal ulcers presenting for care at a primary eye care clinic in rural Nepal were randomised to a standard protocol of antibiotic therapy versus standard therapy plus 2.5% povidone-iodine every 2 hours for 2 weeks. The main outcomes were corrected visual acuity and presence, size, and position of corneal scarring in the affected eye at 2-4 months following treatment initiation. RESULTS:358 patients were randomised and 81% were examined at follow up. The two groups were comparable before treatment. At follow up, 3.9% in the standard therapy and 6.9% in the povidone-iodine group had corrected visual acuity worse than 20/400 (relative risk (RR) 1.77, 95% confidence interval (CI) 0.62 to 5.03). 9.4% in the standard therapy and 13.1% in the povidone-iodine group had corrected visual acuity worse than 20/60 (RR 1.39, 95% CI 0.71 to 2.77), and 17.0% and 18.8% had scars in the visual axis in each of these groups, respectively (RR 1.11, 95% CI 0.67 to 1.82). CONCLUSIONS: A small proportion of patients with corneal ulceration treated in this setting had poor visual outcomes. The addition of povidone-iodine to standard antibiotic therapy did not improve visual outcomes, although this design was unable to assess whether povidone-iodine on its own would have resulted in comparable visual outcomes to that of standard therapy.
RCT Entities:
AIM: To assess whether povidone-iodine provided any benefit over and above a standard regimen of antibiotic therapy for the treatment of corneal ulcers. METHODS: All patients diagnosed with corneal ulcers presenting for care at a primary eye care clinic in rural Nepal were randomised to a standard protocol of antibiotic therapy versus standard therapy plus 2.5% povidone-iodine every 2 hours for 2 weeks. The main outcomes were corrected visual acuity and presence, size, and position of corneal scarring in the affected eye at 2-4 months following treatment initiation. RESULTS: 358 patients were randomised and 81% were examined at follow up. The two groups were comparable before treatment. At follow up, 3.9% in the standard therapy and 6.9% in the povidone-iodine group had corrected visual acuity worse than 20/400 (relative risk (RR) 1.77, 95% confidence interval (CI) 0.62 to 5.03). 9.4% in the standard therapy and 13.1% in the povidone-iodine group had corrected visual acuity worse than 20/60 (RR 1.39, 95% CI 0.71 to 2.77), and 17.0% and 18.8% had scars in the visual axis in each of these groups, respectively (RR 1.11, 95% CI 0.67 to 1.82). CONCLUSIONS: A small proportion of patients with corneal ulceration treated in this setting had poor visual outcomes. The addition of povidone-iodine to standard antibiotic therapy did not improve visual outcomes, although this design was unable to assess whether povidone-iodine on its own would have resulted in comparable visual outcomes to that of standard therapy.
Authors: J Katz; K P West; S K Khatry; S C LeClerq; E K Pradhan; M D Thapa; S Ram Shrestha; H R Taylor Journal: Br J Ophthalmol Date: 1996-12 Impact factor: 4.638
Authors: J Katz; K P West; S K Khatry; M D Thapa; S C LeClerq; E K Pradhan; R P Pokhrel; A Sommer Journal: Invest Ophthalmol Vis Sci Date: 1995-12 Impact factor: 4.799
Authors: Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; Kathryn J Ray; Michael E Zegans; Nisha R Acharya; Thomas M Lietman; Jeremy D Keenan Journal: Ophthalmology Date: 2014-03-05 Impact factor: 12.079
Authors: Shivali A Menda; Manoranjan Das; Arun Panigrahi; N Venkatesh Prajna; Nisha R Acharya; Thomas M Lietman; Stephen D McLeod; Jeremy D Keenan Journal: JAMA Ophthalmol Date: 2020-02-01 Impact factor: 7.389